reading half-life threads from 2024 and half of it aged badly
Something I keep coming back to: reading half-life threads from 2024 and half of it aged badly. Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision. GIP receptor…
Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.
Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.
Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.
Yes. The central component is the one that explains the reports on this site better than gastric emptying does.
Does the effect persist with continued dosing or does tolerance develop?
preclinical is not clinical and rodents are not small people
a mechanism you can state is not a mechanism you have demonstrated
Careful — you have a plausible mechanism and no evidence that it is the operative one in the case you are describing.
Adding the caveat the paper itself makes in its limitations section, which is stronger than anything in this thread.